Primary Sjogren syndrome increases the risk of bisphosphonate-related osteonecrosis of the jaw

Abstract The risk of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in primary Sjogren syndrome (pSS) has rarely been explored. To explore the association between BRONJ and pSS, we conducted a population-based propensity-score-matched cohort study using Taiwan’s National Health Insurance Re...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pei-I Kuo, Tzu-Min Lin, Yu-Sheng Chang, Tsung-Yun Hou, Hui-Ching Hsu, Sheng-Hong Lin, Wei-Sheng Chen, Yi-Chun Lin, Li-Hsuan Wang, Chi-Ching Chang, Jin-Hua Chen
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/623f13a74fd14ee99f8e9a47674313a2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:623f13a74fd14ee99f8e9a47674313a2
record_format	dspace
spelling	oai:doaj.org-article:623f13a74fd14ee99f8e9a47674313a22021-12-02T15:23:01ZPrimary Sjogren syndrome increases the risk of bisphosphonate-related osteonecrosis of the jaw10.1038/s41598-020-80622-52045-2322https://doaj.org/article/623f13a74fd14ee99f8e9a47674313a22021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-80622-5https://doaj.org/toc/2045-2322Abstract The risk of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in primary Sjogren syndrome (pSS) has rarely been explored. To explore the association between BRONJ and pSS, we conducted a population-based propensity-score-matched cohort study using Taiwan’s National Health Insurance Research Database, including pSS patients receiving antiosteoporotic therapy and patients without pSS receiving antiosteoporotic therapy. A 1:4 matched-pair cohort based on propensity score was created. The stratified Cox proportional hazards model compared the risk of BRONJ in the pSS and non-pSS groups. In the study, 23,280 pSS patients and 28,712,152 controls were enrolled. After matching, 348 patients with pSS receiving antiosteoporotic drugs and 50,145 without pSS receiving antiosteoporotic drugs were included for analysis. The risk of developing BRONJ was 1.96 times higher in pSS patients compared with non-pSS patients after adjustment for age, sex, and comorbidities. No dose–response effect was observed in the bisphosphonate-treated pSS cohorts, documented as the cumulative defined daily doses of either < 224 or ≥ 224 (hazard ratio [HR]: 2.407, 95% confidence interval [CI] 1.412–7.790; HR: 2.143, 95% CI 1.046–4.393, respectively) increased risk of developing osteonecrosis of the jaw. In conclusion, the risk of BRONJ is significantly higher in patients with pSS compared with the general population.Pei-I KuoTzu-Min LinYu-Sheng ChangTsung-Yun HouHui-Ching HsuSheng-Hong LinWei-Sheng ChenYi-Chun LinLi-Hsuan WangChi-Ching ChangJin-Hua ChenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Pei-I Kuo Tzu-Min Lin Yu-Sheng Chang Tsung-Yun Hou Hui-Ching Hsu Sheng-Hong Lin Wei-Sheng Chen Yi-Chun Lin Li-Hsuan Wang Chi-Ching Chang Jin-Hua Chen Primary Sjogren syndrome increases the risk of bisphosphonate-related osteonecrosis of the jaw
description	Abstract The risk of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in primary Sjogren syndrome (pSS) has rarely been explored. To explore the association between BRONJ and pSS, we conducted a population-based propensity-score-matched cohort study using Taiwan’s National Health Insurance Research Database, including pSS patients receiving antiosteoporotic therapy and patients without pSS receiving antiosteoporotic therapy. A 1:4 matched-pair cohort based on propensity score was created. The stratified Cox proportional hazards model compared the risk of BRONJ in the pSS and non-pSS groups. In the study, 23,280 pSS patients and 28,712,152 controls were enrolled. After matching, 348 patients with pSS receiving antiosteoporotic drugs and 50,145 without pSS receiving antiosteoporotic drugs were included for analysis. The risk of developing BRONJ was 1.96 times higher in pSS patients compared with non-pSS patients after adjustment for age, sex, and comorbidities. No dose–response effect was observed in the bisphosphonate-treated pSS cohorts, documented as the cumulative defined daily doses of either < 224 or ≥ 224 (hazard ratio [HR]: 2.407, 95% confidence interval [CI] 1.412–7.790; HR: 2.143, 95% CI 1.046–4.393, respectively) increased risk of developing osteonecrosis of the jaw. In conclusion, the risk of BRONJ is significantly higher in patients with pSS compared with the general population.
format	article
author	Pei-I Kuo Tzu-Min Lin Yu-Sheng Chang Tsung-Yun Hou Hui-Ching Hsu Sheng-Hong Lin Wei-Sheng Chen Yi-Chun Lin Li-Hsuan Wang Chi-Ching Chang Jin-Hua Chen
author_facet	Pei-I Kuo Tzu-Min Lin Yu-Sheng Chang Tsung-Yun Hou Hui-Ching Hsu Sheng-Hong Lin Wei-Sheng Chen Yi-Chun Lin Li-Hsuan Wang Chi-Ching Chang Jin-Hua Chen
author_sort	Pei-I Kuo
title	Primary Sjogren syndrome increases the risk of bisphosphonate-related osteonecrosis of the jaw
title_short	Primary Sjogren syndrome increases the risk of bisphosphonate-related osteonecrosis of the jaw
title_full	Primary Sjogren syndrome increases the risk of bisphosphonate-related osteonecrosis of the jaw
title_fullStr	Primary Sjogren syndrome increases the risk of bisphosphonate-related osteonecrosis of the jaw
title_full_unstemmed	Primary Sjogren syndrome increases the risk of bisphosphonate-related osteonecrosis of the jaw
title_sort	primary sjogren syndrome increases the risk of bisphosphonate-related osteonecrosis of the jaw
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/623f13a74fd14ee99f8e9a47674313a2
work_keys_str_mv	AT peiikuo primarysjogrensyndromeincreasestheriskofbisphosphonaterelatedosteonecrosisofthejaw AT tzuminlin primarysjogrensyndromeincreasestheriskofbisphosphonaterelatedosteonecrosisofthejaw AT yushengchang primarysjogrensyndromeincreasestheriskofbisphosphonaterelatedosteonecrosisofthejaw AT tsungyunhou primarysjogrensyndromeincreasestheriskofbisphosphonaterelatedosteonecrosisofthejaw AT huichinghsu primarysjogrensyndromeincreasestheriskofbisphosphonaterelatedosteonecrosisofthejaw AT shenghonglin primarysjogrensyndromeincreasestheriskofbisphosphonaterelatedosteonecrosisofthejaw AT weishengchen primarysjogrensyndromeincreasestheriskofbisphosphonaterelatedosteonecrosisofthejaw AT yichunlin primarysjogrensyndromeincreasestheriskofbisphosphonaterelatedosteonecrosisofthejaw AT lihsuanwang primarysjogrensyndromeincreasestheriskofbisphosphonaterelatedosteonecrosisofthejaw AT chichingchang primarysjogrensyndromeincreasestheriskofbisphosphonaterelatedosteonecrosisofthejaw AT jinhuachen primarysjogrensyndromeincreasestheriskofbisphosphonaterelatedosteonecrosisofthejaw
_version_	1718387328743899136

Primary Sjogren syndrome increases the risk of bisphosphonate-related osteonecrosis of the jaw

Ejemplares similares